- Home
- IMCR vs PAX Comparison
IMCR vs PAX Comparison
Compare IMCR & PAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMCR
- PAX
- Stock Information
- Founded
- IMCR 2008
- PAX 1988
- Country
- IMCR United Kingdom
- PAX Cayman Islands
- Employees
- IMCR N/A
- PAX N/A
- Industry
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- PAX Investment Managers
- Sector
- IMCR Health Care
- PAX Finance
- Exchange
- IMCR Nasdaq
- PAX Nasdaq
- Market Cap
- IMCR 1.8B
- PAX 2.3B
- IPO Year
- IMCR 2021
- PAX 2021
- Fundamental
- Price
- IMCR $33.42
- PAX $15.25
- Analyst Decision
- IMCR Buy
- PAX Strong Buy
- Analyst Count
- IMCR 9
- PAX 1
- Target Price
- IMCR $57.00
- PAX $14.00
- AVG Volume (30 Days)
- IMCR 280.0K
- PAX 544.3K
- Earning Date
- IMCR 11-05-2025
- PAX 11-04-2025
- Dividend Yield
- IMCR N/A
- PAX 5.72%
- EPS Growth
- IMCR N/A
- PAX N/A
- EPS
- IMCR N/A
- PAX 0.53
- Revenue
- IMCR $356,145,000.00
- PAX $397,504,000.00
- Revenue This Year
- IMCR $29.67
- PAX N/A
- Revenue Next Year
- IMCR $11.12
- PAX $21.28
- P/E Ratio
- IMCR N/A
- PAX $28.97
- Revenue Growth
- IMCR 26.78
- PAX 26.52
- 52 Week Low
- IMCR $23.15
- PAX $9.43
- 52 Week High
- IMCR $39.33
- PAX $15.39
- Technical
- Relative Strength Index (RSI)
- IMCR 44.21
- PAX 78.86
- Support Level
- IMCR $35.33
- PAX $13.29
- Resistance Level
- IMCR $36.76
- PAX $14.58
- Average True Range (ATR)
- IMCR 1.57
- PAX 0.30
- MACD
- IMCR -0.20
- PAX 0.15
- Stochastic Oscillator
- IMCR 24.65
- PAX 93.11
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
About PAX Patria Investments Limited
Patria Investments Ltd is an alternative asset management firm specializing in resilient sectors across select regions. It seeks to provide world-wide and Latin American investors with attractive investment products that allows portfolio diversification and consistent returns. The group promotes inclusive and sustainable development in the Asset Classes: Private Equity, Private Equity Solutions, Credit, Real Estate, Infrastructure, and Public Equities Main sectors: Agribusiness, Power & Energy, Healthcare, Logistics & Transportations, Food & Beverage and Digital & Tech Services Investment Regions.